| Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate … VD Handratta, TS Vasaitis, VCO Njar, LK Gediya, R Kataria, P Chopra, ... Journal of medicinal chemistry 48 (8), 2972-2984, 2005 | 331 | 2005 |
| CYP17 inhibitors for prostate cancer therapy TS Vasaitis, RD Bruno, VCO Njar The Journal of steroid biochemistry and molecular biology 125 (1-2), 23-31, 2011 | 256 | 2011 |
| Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases VCO Njar, L Gediya, P Purushottamachar, P Chopra, TS Vasaitis, ... Bioorganic & medicinal chemistry 14 (13), 4323-4340, 2006 | 205 | 2006 |
| Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16 … T Vasaitis, A Belosay, A Schayowitz, A Khandelwal, P Chopra, LK Gediya, ... Molecular cancer therapeutics 7 (8), 2348-2357, 2008 | 169 | 2008 |
| Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy OO Clement, CM Freeman, RW Hartmann, VD Handratta, TS Vasaitis, ... Journal of medicinal chemistry 46 (12), 2345-2351, 2003 | 130 | 2003 |
| Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to … P Purushottamachar, AM Godbole, LK Gediya, MS Martin, TS Vasaitis, ... Journal of medicinal chemistry 56 (12), 4880-4898, 2013 | 126 | 2013 |
| Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and … RD Bruno, TS Vasaitis, LK Gediya, P Purushottamachar, AM Godbole, ... Steroids 76 (12), 1268-1279, 2011 | 96 | 2011 |
| Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors VMA Moreira, TS Vasaitis, VCO Njar, JAR Salvador steroids 72 (14), 939-948, 2007 | 80 | 2007 |
| CYP17 inhibitors for prostate cancer treatment-an update VM Moreira, JAR Salvador, TS Vasaitis, VCO Njar Current Medicinal Chemistry 15 (9), 868-899, 2008 | 67 | 2008 |
| Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells Q Wang, TS Udayakumar, TS Vasaitis, AM Brodie, JD Fondell Journal of Biological Chemistry 279 (17), 17319-17328, 2004 | 60 | 2004 |
| Evidence for threshold effects of 25-hydroxyvitamin D on glucose tolerance and insulin resistance in black and white obese postmenopausal women JD Sorkin, TS Vasaitis, E Streeten, AS Ryan, AP Goldberg The Journal of nutrition 144 (5), 734-742, 2014 | 46 | 2014 |
| Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments TS Vasaitis, VCO Njar Future medicinal chemistry 2 (4), 667-680, 2010 | 46 | 2010 |
| Synthesis of novel C17 steroidal carbamates: Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth VMA Moreira, TS Vasaitis, Z Guo, VCO Njar, JAR Salvador Steroids 73 (12), 1217-1227, 2008 | 42 | 2008 |
| Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent P Purushottamachar, A Khandelwal, TS Vasaitis, RD Bruno, LK Gediya, ... Bioorganic & medicinal chemistry 16 (7), 3519-3529, 2008 | 39 | 2008 |
| The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer A Brodie, V Njar, LF Macedo, TS Vasaitis, G Sabnis Urologic Oncology: Seminars and Original Investigations 27 (1), 53-63, 2009 | 37 | 2009 |
| First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents P Purushottamachar, A Khandelwal, P Chopra, N Maheshwari, LK Gediya, ... Bioorganic & medicinal chemistry 15 (10), 3413-3421, 2007 | 35 | 2007 |
| Phytoalexins, miRNAs and breast cancer: a review of phytochemical-mediated miRNA regulation in breast cancer SL Tilghman, LV Rhodes, MR Bratton, P Carriere, LC Preyan, SM Boue, ... Journal of health care for the poor and underserved 24 (1 0), 36, 2013 | 32 | 2013 |
| Galeterone and the next generation galeterone analogs, VNPP414 and VNPP433-3β exert potent therapeutic effects in castration-/drug-resistant prostate cancer preclinical models … AK Kwegyir-Afful, S Ramalingam, VP Ramamurthy, P Purushottamachar, ... Cancers 11 (11), 1637, 2019 | 23 | 2019 |
| The novel Mnk1/2 degrader and apoptosis inducer VNLG-152 potently inhibits TNBC tumor growth and metastasis S Ramalingam, VP Ramamurthy, LK Gediya, FN Murigi, ... Cancers 11 (3), 299, 2019 | 21 | 2019 |
| Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitor VN/124-1 in prostate cancer T Vasaitis, A Belosay, A Schayowitz, A Khandelwal, P Chopra, LK Gediya, ... Molecular cancer therapeutics 7 (8), 2348, 2008 | 13 | 2008 |
